公开(公告)号：US20050222035A1

公开(公告)日：2005-10-06

申请号：US11127702

申请日：2005-05-11

申请人： Thomas Boone ,  Kenneth Wild ,  Karen Sitney ,  Hosung Min ,  Bruce Kimmel

发明人： Thomas Boone ,  Kenneth Wild ,  Karen Sitney ,  Hosung Min ,  Bruce Kimmel

IPC分类号： A61K38/00 ,  C07H21/04 ,  C07K7/08 ,  C07K14/00 ,  A61K38/10

CPC分类号： C07K16/22 ,  A61K38/00 ,  C07H21/04 ,  C07K7/08 ,  C07K14/001

摘要： The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.

公开(公告)号：US20080102492A1

公开(公告)日：2008-05-01

申请号：US11977872

申请日：2007-10-26

申请人： Joan Egrie ,  Steven Elliott ,  Jeffrey Browne ,  Karen Sitney

发明人： Joan Egrie ,  Steven Elliott ,  Jeffrey Browne ,  Karen Sitney

IPC分类号： C12P21/04 ,  C12N15/00 ,  C12N15/11 ,  C12N5/06

CPC分类号： C07K14/505 ,  C07K2319/30 ,  C12N15/62

摘要： Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

摘要翻译： 公开了增加和维持哺乳动物血细胞比容的方法，包括施用红血球生成素的高糖蛋白类似物。 类似物可以比等效摩尔量的重组人促红细胞生成素施用频率更低，以获得可比较的目标血细胞比容并治疗贫血。 或者，可以施用较低摩尔量的高糖基化类似物以获得可比较的目标血细胞比容并治疗贫血。 还公开了新的高糖基化促红细胞生成素类似物，类似物的生产方法和包含类似物的组合物。

公开(公告)号：US20060140934A1

公开(公告)日：2006-06-29

申请号：US11234731

申请日：2005-09-23

申请人： Colin Gegg ,  Fei Xiong ,  Karen Sitney

发明人： Colin Gegg ,  Fei Xiong ,  Karen Sitney

IPC分类号： A61K39/395 ,  G01N33/53 ,  C40B40/10

CPC分类号： C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2318/10 ,  C07K2319/30

摘要： The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacologic agent comprising an amino acid sequence of the selected peptide in a loop region of an Fc domain. This process may be employed to modify an Fc domain that is already linked through an N— or C-terminus or sidechain to a peptide or to a polypeptide (e.g., etanercept). This process may also be employed to modify an Fc domain that is part of an antibody (e.g., adalimumab, epratuzumab, infliximab, Herceptin®, and the like). In this way, different molecules can be produced that have additional functionalities, such as a binding domain to a different epitope or an additional binding domain to the precursor molecule's existing epitope. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.

摘要翻译： 本发明涉及分子和一种或多种生物活性肽并入Fc结构域的方法。 在本发明中，药理学活性化合物可以通过以下方法制备：（a）选择至少一种调节目的蛋白质活性的肽; 和（b）在Fc结构域的环区中制备包含所选肽的氨基酸序列的药理学试剂。 该方法可以用于修饰已经通过N-或C-末端或侧链连接到肽或多肽（例如依那西普）的Fc结构域。 该方法也可用于修饰作为抗体一部分的Fc结构域（例如阿达木单抗，依普珠单抗，英夫利昔单抗，赫赛汀等）。 以这种方式，可以产生具有额外功能的不同分子，例如与不同表位的结合结构域或与前体分子存在的表位的附加结合结构域。 肽可以例如通过噬菌体展示，大肠杆菌展示，核糖体展示，RNA-肽筛选，酵母筛选，化学肽筛选，合理设计或蛋白质结构分析来选择。